

Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents

Addition of Aalto Bio Reagents expands Biosynth Carbosynth's offer to its clinical diagnostics customers.

Staad, 25 May 2022 - Biosynth Carbosynth ("Biosynth"), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents ("Aalto"), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.

The acquisition represents a further milestone in Biosynth's development, which broadens its capabilities and offering to the IVD industry. Aalto's product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.

Dr. Urs Spitz, CEO and President of Biosynth, said, "This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry."

Philip Noone, CEO of Aalto, added, "We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto's industry leading products and key focus on emerging disease are an excellent fit with Biosynth's products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future."

--ends--

About Biosynth Carbosynth

Biosynth Carbosynth is a supplier of critical materials to the life science industry with global research, manufacturing and distribution facilities. It is the supplier of choice for many in the pharmaceutical and diagnostic sectors and manufactures and sources a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, enzyme substrates, peptides, phospholipids, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Headquartered in Staad, Switzerland, Biosynth Carbosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth Carbosynth at www.biosynth-carbosynth.com.

About Aalto Bio Reagents

Aalto Bio Reagents, founded in 1978, is a leading developer and provider of biological raw materials to the in-vitro diagnostics industry and to research laboratories globally. It serves the largest multinational companies in the industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit <http://www.aaltobioreagents.com>

Media Contacts

Biosynth Carbosynth
Aimee Cossins
+44 7984 525560
marketing@biosynth-carbosynth.com